3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
13
Rituximab
11
obinutuzumab
6
fludarabine phosphate
6
fludarabine
6
Prednisone
6
ibrutinib
5
X-Rays
5
Whole-Body Irradiation
5
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Melphalan
5
Magnetic Resonance Spectroscopy
5
Lenalidomide
5
Etoposide
5
Biopsy
5
tocilizumab
4
polatuzumab vedotin
4
Doxorubicin
4
Bendamustine Hydrochloride
4
venetoclax
3
glofitamab
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Leukapheresis
3
Filgrastim
3
Cytarabine
3
Cyclosporine
3
Busulfan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
R-CHOP protocol
×
30 days
×
Clear all
NCT04661007
2026-05-18
J-MIND
Incyte Corporation
Phase 1/2
Active not recruiting
72 enrolled